The company said that it acquired Nottingham, UK-based Midland in order to lower its future manufacturing expenses and reduce risk to its supply chain.
Revenues were up to $587 million in the quarter, compared to $584 million in Q4 2014. Foreign currency effects reduced Q4 2015 revenues by around 5 percent.
The investment bank also initiated coverage of Agilent Technologies, Bruker, Illumina, PerkinElmer, and Waters with a Hold rating.
These designations mean the system can be sold in the US and Europe for use in laboratory-developed tests including, for instance, protein-based diagnostics.
The company posted revenues of $500.6 million, up from $493.2 million in Q3 2014. Currency effects contributed to a roughly 7 percent reduction in sales growth.
Overall, analyst Bryan Brokmeier said he is bullish on the space in spite of uncertainty in the general global markets.
The upgrade follows four consecutive quarters of above-industry-average revenue growth, driven by the biopharma end market, and the addition of a new CEO.
The company posted second quarter revenues of $494.7 million, up from $481.8 million in Q2 2014 and beating the average Wall Street estimate of $481.7 million.
Waters has signed an instrument control agreement with Agilent and recognized Chang Gung University as a Center of Innovation Partner.
The conference was relatively light on new mass spec launches, with many vendors focusing instead on more targeted applications of existing technology.
The former commissioner of the FDA has returned to the venture capital firm New Enterprise Associates as a special partner on the healthcare investment team.
Astronauts have edited yeast genes on the International Space Station in an experiment designed to show how cells repair themselves in space.
Emory University has found that two of its researchers failed to divulge they had received funds from China, according to the Atlanta Journal-Constitution.
In Science this week: influence of the nuclear genome on human mitochondrial DNA, and more.